To investigate the use of docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in real-world clinical practice in China.
INTRODUCTION
In China, the incidence of prostate cancer has increased over the past 40 years, with current estimates citing 47 000 new cases annually, and is currently the seventh most frequently diagnosed cancer for men. [1] [2] [3] [4] Furthermore, data collected in major cities including Beijing, Shanghai and Guangzhou suggest that around 68% of Chinese patients present with advanced prostate cancer at diagnosis. 5, 6 Nearly 90% of all patients with metastatic prostate cancer initially respond to hormonal therapy; implemented surgically with bilateral orchiectomy, or medically with luteinizing hormone-releasing hormone (LHRH) agonists or antagonists to maintain serum testosterone levels at castrate levels of <50 ng/dL. [7] [8] [9] However, most men with advanced prostate cancer eventually experience disease progression to castration-resistant prostate cancer (CRPC), in a median of 18-24 months; defined as castrate levels of serum testosterone with rising prostate-specific antigen (PSA) levels, progression of preexisting disease or appearance of new metastatic disease. [7] [8] [9] [10] [11] Until recently, metastatic CRPC (mCRPC) was associated with a very poor prognosis, and treatment was palliative only.
Based on the two landmark phase III trials TAX 327 and SWOG 9916 and subsequent studies the combination of docetaxel and prednisone every 3 weeks was established as a recommended first-line treatment for mCRPC. [12] [13] [14] [15] [16] [17] A more recent Chinese Phase III study demonstrated that docetaxel-based treatment led to a significantly greater PSA response rate compared with mitoxantrone (P = 0.021), which supported the approval of docetaxel as a first-line therapy for mCPRC in China in 2010. 18 More recently, treatment options for mCRPC have expanded to include secondary hormonal therapy, abiraterone acetate, cabazitaxel, enzalutamide, radium-223 and sipuleucel-T, [7] [8] [9] 16 however, of these only abiraterone is currently approved in China for the treatment of mCRPC.
In real-world clinical practice in China, the majority of patients with prostate cancer are treated in urology departments where urologists often prefer to re-use hormonal therapy rather than initiate chemotherapy; therefore, docetaxel is commonly used after second-, third-or subsequent-line hormonal therapy. In addition, the hormonal chemotherapy drug estramustine is used frequently due to the relatively late approval of docetaxel in China. However, data on the realworld use of docetaxel in mCRPC in China are scarce and since the approval of docetaxel for mCRPC in China, there has been no observational study to investigate its use in clinical practice. Such realworld data would provide valuable insights into adherence to clinical guideline recommendations as well as treatment patterns and real-world use of docetaxel, and help identify unmet clinical needs and areas for development. The present study was therefore conducted to evaluate the patterns of use, effectiveness and safety of docetaxel for treatment of mCRPC in real-life clinical practice in China.
METHODS

Study design and patients
This was a single-arm, prospective, multicenter, observational study conducted in China. The study included adult patients (≥18 years) with histologically confirmed metastatic prostate adenocarcinoma who had received ≥1 dose of docetaxel (Taxotere R , Sanofi, France) following failure of hormonal therapy (disease progression and serum testosterone <50 ng/dL). Patients with a history of hypersensitivity to docetaxel, with neuroendocrine differentiation, or those who were participating or planning to participate in other clinical trials were excluded.
During the study, docetaxel was administered in accordance with the local product label (docetaxel 75 mg/m 2 every 3 weeks IV, plus prednisone 5 mg twice a day) and at the discretion of the investigator.
The study protocol was approved by the institutional review boards of 
Study endpoints
The primary goal of this study was to investigate the patterns of use of docetaxel in Chinese patients with mCRPC. Other endpoints included overall survival, PSA response rate (defined as a reduction in serum PSA of at least 50% maintained on two occasions at least 3 weeks apart, with transient increases in PSA in the first 12 weeks ignored, as per Working Group guidelines 20 and only including patients who had PSA ≥20 ng/mL at Baseline in-line with the Tax 327 study 14 ), investigation of baseline factors that may influence patient survival and PSA response rate, reasons for docetaxel discontinuation, patterns of treatment selection following docetaxel failure and safety endpoints.
Data collection
Patient data were collected at the enrollment visit, an end of treatment visit (<30 days from the last dose of docetaxel), and at followup visits every 6 ± 2 months after the end of treatment until patient death, discontinuation, or 2 years after enrollment of the last patient.
Patients were grouped according to the following expected docetaxel treatment settings: docetaxel following failure of first-line hormonal therapy (i.e., patients treated with hormonal therapy who then experienced progression to mCRPC and subsequently received docetaxel), following failure of second-and third-line hormonal therapies, following failure of estramustine therapy and "other" settings. The "other" category was defined as all patients lacking sufficient information to classify the docetaxel treatment setting.
Subgroup analyses were performed to evaluate OS and PSA response of docetaxel therapy by treatment setting, Gleason score, age, evidence of metastasis to local lymph nodes, evidence of distant metastasis, involvement of visceral metastasis in patients with distal metastasis and ECOG score.
Statistical methods
The primary analysis population included all patients who received a docetaxel-based regimen after enrollment. The PSA population included all patients with a PSA level ≥20 ng/mL within 1 month prior to the use of docetaxel and excluded patients with lower levels or with missing data. The safety population included patients who received at least one dose of docetaxel.
Data were summarized and presented in frequency tables with frequency and percentage provided for categorical variables and mean (SD) for continuous variables, unless specified. Docetaxel treatment compliance was calculated as the actual total dose received as a percent of the scheduled dose. Kaplan-Meier curves were used to estimate rates of overall survival, and inter-subgroup differences in patient survival were assessed using the log-rank test; patients with missing data or lost to follow up were censored. All statistical tests were two-sided, and P < 0.05 was considered to be statistically significant. Type I errors were not corrected in this exploratory study.
Based on an assumed range of patients in each treatment setting of 15-40%, a <25% relative error for the proportion of patients in each treatment setting and a 95% confidence level, a sample size of 400 patients was calculated to provide a 95% CI of 11.5% to 18.5% for the calculation of the proportion of patients in each treatment setting. Table 1 .
RESULTS
Patients
Patterns of docetaxel use
The majority of patients initiated treatment with docetaxel after failure of first-line (42.2%) or second-line hormonal therapy (31.0%), with a minority initiating docetaxel after failure of ≥third-line hormonal therapy (12.7%) or estramustine therapy (11.4%; Figure 1A ).
Among the 170 patients who initiated docetaxel after failure of first-line hormonal therapy, the majority (94.7%) had received pharmaceutical hormonal therapies, with bicalutamide (79.4%), goserelin (43.5%) and flutamide (23.5%) the most common ( Figure 1B ). Hormonal therapy with surgical and medical procedures was received by 33.5% of patients, including bilateral orchidectomy (note that patients may have received ≥1 hormonal therapies; Figure 1C ). Almost all 
Docetaxel exposure, reasons for discontinuation and concomitant medications
The median number of docetaxel cycles received following enrollment was 4.0 (range: 1-18), the mean total dose was 66.9 mg/m 2 (SD = 9.12), and the median dose by body surface area was 67.7 mg/m 2 (26.7-133.3; Table 2 ). The rate of treatment compliance in terms of total docetaxel dose received versus planned total dose was 94%. No differences in PSA response rate were observed for the other subgroups investigated (Table 4 ).
Docetaxel effectiveness
Treatment patterns following docetaxel treatment failure
There were 31 (7.7%) patients who received at least one dose of anticancer therapy after docetaxel treatment failure, with hormonal therapies (n = 14), antineoplastic agents (n = 11) and drugs for treatment of bone disease being the most common. Following docetaxel failure, the most frequently used hormonal therapies were prednisone (n = 3) and triptorelin (n = 3) and the most common antineoplastic agent was docetaxel (n = 5).
Safety
Overall 
DISCUSSION
Prostate cancer has emerged as a major health problem worldwide, particularly in China where its incidence is increasing and is associated with more advanced disease, poorer prognosis and shorter survival compared with patients in Western countries. 1, 2, 4 Although docetaxel is recommended as a first-line therapy for the treatment mCRPC in international and Chinese guidelines, [15] [16] [17] Chinese registration study 18 and is longer than results from the pivotal TAX327 and SWOG 9916 phase III studies (19.2 and 17.5 months, respectively). 12, 13 In addition, the PSA response rate of 70.9% was twice as high as reported in the Chinese registration study (35.1%) 18 and noticeably higher than the 25.7-50% response rates reported for patients in the docetaxel arms of other phase II and III trials, although it should be noted that the PSA response rate in this study was calculated only for patients with available PSA data. 13, 14, 21, 22 In contrast, a similar PSA response rate of 69.5% was previously reported in the CALGB 90401 study, with the addition of bevacizumab to docetaxel and prednisone. 23 However, it should be noted that the median PSA level at
Baseline was comparatively lower in this study than in these previous studies in Chinese and Caucasian patients (61.0 ng/mL vs. 70.9-168 ng/mL), which may explain the relatively higher rate of patients who attained a ≥50% reduction in serum PSA in this study. 13, 14, 18, 21 Subgroup analyses revealed that mOS and PSA response rate were not associated with docetaxel treatment setting, Gleason score, age group, ECOG score or evidence of distant metastasis. The mOS and PSA responses observed in this study and key phase III trials suggest that docetaxel-based treatment is beneficial in patients with mCRPC who have received up to and beyond three previous lines of hormonal therapy. [15] [16] [17] This is important as most international and local guidelines recommend continuing hormonal therapy as one of the first-line treatment options and, more recently, second-line hormonal therapies have shown effectiveness for mCRPC. [7] [8] [9] These results have clinical implications in China where primary treatment is typically hormonal therapy initiated by urologists.
Although treatment compliance was high at 94.0%, the overall docetaxel exposure (4.4 (2.86) cycles of docetaxel at a mean dose of 66.9 mg/m 2 ) was below the recommended dosage of docetaxel 75 mg/m 2 every 3 weeks for up to 10 cycles. [15] [16] [17] The number of treatment cycles received was also lower than reported in previous phase III studies (median 8-9.5). 14, 18, 23 The main reasons reported for early treatment discontinuation in this study were "inability to afford medical expenses" (22.6%) followed by disease progression (14.1%). These results reflect the real-world challenges faced by patient and clinicians when making treatment decisions, particularly in developing countries like China.
This study has several limitations which deserve mention. First, the observational design of the study is associated with potential biases from the process of patient recruitment and data collection, particularly because survival and PSA data were not available for all patients and a number of patients were lost to follow-up. In addition, although subgroup analyses suggest that particular patient and disease charac-teristics may be associated with docetaxel treatment outcomes, causal inferences cannot be reliably drawn. Finally, the study also did not assess the influence of the neutrophil-to-lymphocyte ratio on survival, which has been regarded as an important prognostic factor in patients with mCRPC. 24, 25 This study provides important information on the patterns of docetaxel use in patients with mCRPC in real-world clinical practice in China, and provides evidence of its safety and effectiveness in this setting. However, it must be noted that the treatment landscape for mCRPC has evolved rapidly over the past 5 years and first-line treatment options are no longer limited to docetaxel-based chemotherapy. 8, 9 New AR-targeted agents, such as abiraterone and enzalutamide, have demonstrated clinical benefit in chemotherapy refractory mCRPC patients. 26, 27 Other new therapies, including cabazitaxel, radium-223, and sipuleuce-T, have also been approved by regulatory authorities, [7] [8] [9] 16 although only abiraterone is currently approved in China (it should also be noted that abiraterone was only approved in China in 2015 and entered clinical use in 2016). Treatment decisions for patients with mCRPC are therefore often based on multiple factors, including patient health status, tumor status, tolerability, and responses to individual treatment, and health economic factors.
The data generated in this study provide valuable real-world insights which can inform clinician decision-making regarding the clinical application of docetaxel and associated outcomes in Chinese patients with mCRPC.
